Biological activity of anomeric pairs of lipophilic glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine

Bulletin of Experimental Biology and Medicine

Volumn 145, Issue 5, 2008, Pages 623-625

  Kalyuzhin, O V ^a   Zemlyakov, A E ^b   Kalina, N G ^c   Mulik, E L ^a   Kuzovlev, F N ^a   Makarova, O V ^a  

^a RESEARCH INSTITUTE OF HUMAN MORPHOLOGY   (Russian Federation)

^b TAURIDA NATIONAL V I VERNADSKY UNIVERSITY   (Ukraine)

^c MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA   (Russian Federation)

Author keywords

Escherichia coli; Lipophilic and glycosides; Muramyl dipeptide; Resistance; Staphylococcus aureus

Indexed keywords

ALPHA (1 PENTYLHEXYL)GLYCOSIDE; ALPHA CYCLODODECYL GLYCOSIDE; ALPHA DODECYL GLYCOSIDE; ANTIINFECTIVE AGENT; BETA (1 PENTYLHEXYL)GLYCOSIDE; BETA CYCLODODECYL GLYCOSIDE; BETA DODECYL GLYCOSIDE; GLYCOPEPTIDE; GLYCOSIDE; MURAMYL DIPEPTIDE DERIVATIVE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENTEROBACTER INFECTION; ESCHERICHIA COLI; IMMUNOSTIMULATION; LIPOPHILICITY; LOW DRUG DOSE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; SEPSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI INFECTIONS; GLYCOSIDES; MICE; MOLECULAR STRUCTURE; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; ESCHERICHIA COLI; MUS; STAPHYLOCOCCUS AUREUS;

EID: 55649094872     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-008-0157-8     Document Type: Article

References (10)

1. A. E. Zemlyakov, V. N. Tsikalova, V. V. Tsikalov, et al., Bioorgan. Khim., 32, No. 4, 424-431 (2006).
2. A. E. Zemlyakov, V. V. Tsikalov, V. Ya. Chirva, et al., Ibid., 31, No. 6, 1-7 (2005).
3. O. V. Kalyuzhin, A. E. Zemlyakov, E. V. Kalyuzhina, et al., Byull. Eksp. Biol. Med., 134, No. 8, 186-190 (2002).
4. O. V. Kalyuzhin, N. G. Kalina, A. F. Bashtanenko, et al., Ibid., 135, No. 5, 531-535 (2003).
5. O. V. Kalyuzhin, V. V. Kalyuzhin, A. E. Zemlyakov, et al., Ibid., 127, No. 5, 543-545 (1999).
6. O. V. Kalyuzhin, M. V. Nelyubov, E. V. Kalyuzhina, et al., Ibid., 134, No. 9, 326-328 (2002).
7. O. V. Kalyuzhin, B. B. Fuchs, N. V. Bovin, et al., Ibid., 117, No. 5, 510-513 (1994).
8. R. M. Khaitov, I. S. Gushchin, B. F. Pinegin, and A. I. Zebrev, Manual on Experimental (Preclinical) Study of New Pharmacological Substances [in Russian], Moscow (2000), pp. 257-263.
9. W. E. Fogler and I. J. Fidler, Int. J. Immunopharmacol., 9, No. 2, 141-150 (1987).
10. O. V. Kalyuzhin, A. E. Zemlyakov, and B. B. Fuchs, Ibid., 18, No. 11, 651-659 (1996).